Tryptamine Therapeutics Enrolls First Patient in Groundbreaking BED Trial

• First patient enrolled in world-first IV psilocin trial for Binge Eating Disorder
• Trial to recruit 12 patients across two dosing cohorts with supportive therapy
• Primary focus on safety and tolerability, with secondary efficacy endpoints
• TRP-8803 offers rapid onset and controllable dosing advantages over oral psilocybin